Opdivo/Cabometyx Combo ‘Very Encouraging' In 1L RCC
But Competition Intensifying
Executive Summary
Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.